Company & Sponsor Intelligence
Erasmus Medical Center
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials7
Recruiting1
Completed2
Countries2
Therapeutic footprint
anxietydepressionother_neurologyout_of_scopeschizophreniastroke
Indexed studies
NCT02256124Effect of Lamotrigine on Cognition in NF1
other_neurology · BelgiumPHASE2, PHASE3
other_neurology · BelgiumPHASE2, PHASE3
NCT02436746The Cognitive Variability in NF1 and TSC Monozygotic Twins
other_neurology · NetherlandsUNKNOWN
other_neurology · NetherlandsUNKNOWN
NCT03764644Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
anxiety · NetherlandsNA
anxiety · NetherlandsNA
NCT02119949Working Memory Training for Substance Dependent Individuals
depression · NetherlandsNA
depression · NetherlandsNA
NCT06749197Implementation of a Home-based Computerized Cognitive Rehabilitation Program for Patients With ABI
stroke · NetherlandsNA
stroke · NetherlandsNA
NCT03108547Hair Cortisol and Testosterone Levels in Patients With Sarcoidosis
out_of_scope · COMPLETED
out_of_scope · COMPLETED
NCT03628391Haloperidol for Delirium in Adult Critically Ill Patients
schizophrenia · NetherlandsPHASE3
schizophrenia · NetherlandsPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →